Myasthenia Gravis Disease Market Share

ID: MRFR/Pharma/4387-HCR

200 Pages

Rahul Gotadki

October 2025

Myasthenia Gravis Disease Market Research Report By Treatment Type (Immunosuppressants, Cholinesterase Inhibitors, Monoclonal Antibodies, Plasmapheresis, Intravenous Immunoglobulin), By Diagnosis Method (Electromyography, Blood Tests, CT Scan, MRI, Edrophonium Test), By Patient Demographics (Adults, Children, Elderly), By Distribution Channel (Hospitals, Pharmacies, Online Stores), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Myasthenia Gravis Disease Market Infographic

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Share

Myasthenia Gravis Disease Market Share Analysis

The Myasthenia Gravis Disease Market is undergoing significant transformative processes caused by the advance in medical research, better autoimmune disease understanding and patient outcomes’ enhancement commitment. This has led to increased interest in treatment and management options for chronic autoimmune neuromuscular disease known as myasthenia gravis (MG), thereby driving market growth. A new trend in this area encompasses investigations into innovative therapeutic alternatives that move beyond traditional methods.

Additionally, mononuclear antibodies are some of the immunotherapies that have been increasingly used to treat myasthenia gravis disease targeting specific components within the immune system. Through a targeted approach, maximal therapeutic efficacy while minimizing generalized immunosuppression associated side effects can be achieved.” This direction follows current trends in managing autoimmune diseases where the response of the market to immunotherapies emphasizes personalized treatment plans as well as precision medicine.

Besides, developments are going on regarding diagnostic tools that help in early and accurate identification of MG aiding timely intervention. Electromyography imaging studies along with serological tests are requested for confirming muscle paralysis diagnosis and assessing its severity level. There is a paradigm shift towards patient-centered care in managing MG through market dynamics transformation. Indeed, advocacy programs, patient education initiatives, and support services feature among crucial elements constituting holistic care package for individuals diagnosed with MG. On one hand providing patients with relevant information materials plus other useful resources enhances their ability to effectively deal with their condition while on the other hand it cultivates self-awareness and active engagement in the decision-making process of their health. The myasthenia gravis disease market is being impacted by the demographic transition toward an aging population, given that the disease is more prevalent among elderly individuals. As the global population ages, there is a growing emphasis on customizing treatment strategies to effectively address the distinct requirements and obstacles that arise in the management of MG in elderly patients. Hence, pharmaceutical companies are directing their efforts towards research and development aimed at producing therapies that are effective yet tolerable to this group.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected growth of the Myasthenia Gravis Disease market?

The Myasthenia Gravis Disease market is the expected increase in total market value of 3.07 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Myasthenia Gravis Disease market?

Myasthenia Gravis Disease market size was valued at approximately 1.33 billion USD in 2024. This figure will reach 3.07 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Myasthenia Gravis Disease market?

Myasthenia Gravis Disease market is expected to grow at a CAGR of 7.92% between 2025 and 2035.

How much will the Myasthenia Gravis Disease market be worth by 2035?

Myasthenia Gravis Disease market is expected to be worth of 3.07 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Myasthenia Gravis Disease market perform over the next 10 years?

Over the next 10 years the Myasthenia Gravis Disease market is expected to shift from usd billion 1.33 to 3.07 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the market size of the Myasthenia Gravis Disease Market in 2024?

The Myasthenia Gravis Disease Market was valued at 2.01 billion USD in 2024.

What is the projected market valuation for the Myasthenia Gravis Disease Market by 2035?

By 2035, the Myasthenia Gravis Disease Market is projected to reach a valuation of 3.8 billion USD.

Which region held the largest market share in 2024 for the Myasthenia Gravis Disease Market?

North America held the largest market share in 2024, valued at 0.85 billion USD.

What is the expected value of the Myasthenia Gravis Disease Market in Europe by 2035?

By 2035, the Myasthenia Gravis Disease Market in Europe is expected to reach a value of 1.05 billion USD.

Who are the key players in the Myasthenia Gravis Disease Market?

Key players include Pfizer, Mallinckrodt Pharmaceuticals, Bristol-Myers Squibb, Amgen, and UCB.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future Analysis, the Myasthenia Gravis Disease Market was valued at 1.33 USD Billion in 2024 and is projected to grow to 3.07 USD Billion by 2035, reflecting a CAGR of 7.92% from 2025 to 2035. The market is driven by increasing prevalence, advancements in treatment options, and rising awareness initiatives.

Key Market Trends & Highlights

The Global Myasthenia Gravis Disease Market is experiencing transformative trends.

The market is expected to reach 2.01 USD Billion in 2024, driven by rising treatment demand. Immunosuppressants are projected to grow from 0.8 USD Billion in 2024 to 1.5 USD Billion by 2035. North America is the largest regional market, valued at 0.85 USD Billion in 2024, expected to reach 3.07 USD Billion by 2035. Educational initiatives have led to a 30% higher early diagnosis rate in communities with awareness programs.

Myasthenia Gravis Disease Market

CAGR

7.92%

Market Size & Forecast

2024 Market Size	USD 1.33 Billion
2035 Market Size	USD 3.07 Billion
CAGR (2025-2035)	7.92%
Largest Regional Market Share in 2024	North America.

Major Players

Key players include Genentech, Pfizer, Merck and Co, Baxter International, Roche, Eli Lilly, Johnson and Johnson, Boehringer Ingelheim, Meda Pharmaceuticals, UCB, Teva Pharmaceutical Industries, Novartis, Bristol-Myers Squibb, Amgen, and Sanofi.

Market Trends

Currently, a number of significant market factors are driving the Myasthenia Gravis Disease Market, with the illness's rising prevalence being the main worry. Initiatives aimed at improving myasthenia gravis diagnostic and treatment choices are a result of governments and health organizations throughout the world realizing the need for improved healthcare services.

This increased awareness encourages research and development, which in turn makes therapeutic innovation possible. Additionally, the increased focus on customized medicine is encouraging research into targeted medicines, which are essential for treating the particulars of each patient's illness.There are a lot of market opportunities, especially in developing nations with developing healthcare systems. These nations are starting to pay greater attention to neurological conditions, which may result in patients having access to more sophisticated medical treatment and drugs.

Partnerships between academic institutions and pharmaceutical corporations can also promote clinical studies aiming at improving illness management and speed up the discovery of novel therapies. Particularly in the aftermath of the pandemic, recent trends show an increasing acceptance of digital health and telemedicine technologies, which make it easier for people to consult medical specialists.

Better access to care and improved condition management have been made possible by this change. The growth of patient advocacy organizations and social media also contributes to raising community knowledge and support, which has a favorable effect on financing for research and policy choices.All things considered, these patterns highlight a changing environment that is adapting to better meet the requirements of people with myasthenia gravis across the world.

Myasthenia Gravis Disease Market Market Drivers

Market Trends and Projections

The Global Myasthenia Gravis Disease Market Industry is characterized by various trends that indicate a positive growth trajectory. Current projections suggest that the market will achieve a value of 2.01 USD Billion in 2024, with an anticipated CAGR of 5.96% from 2025 to 2035. This growth is driven by factors such as increasing prevalence, advancements in treatment options, and supportive government policies. The market's expansion reflects the ongoing commitment to improving patient care and developing innovative therapies. As the industry evolves, it is essential to monitor these trends to understand their implications for future market dynamics.

Supportive Government Policies

Government initiatives aimed at improving healthcare access and funding for rare diseases are positively impacting the Global Myasthenia Gravis Disease Market Industry. Policies that promote research funding and support for clinical trials are essential for advancing treatment options. For example, various countries have established rare disease registries and funding mechanisms to facilitate research. These supportive measures are likely to enhance the development of new therapies, thereby expanding the market. As the industry grows, it is anticipated that the market will reach a valuation of 2.01 USD Billion in 2024, reflecting the positive influence of government involvement in healthcare.

Growing Awareness and Diagnosis

The Global Myasthenia Gravis Disease Market Industry benefits from increasing awareness among healthcare professionals and the general public. Enhanced educational initiatives and advocacy efforts are leading to earlier diagnosis and treatment, which is crucial for managing the disease effectively. As more individuals recognize the symptoms and seek medical advice, the number of diagnosed cases is expected to rise. This trend is likely to contribute to the market's expansion, with projections indicating a compound annual growth rate (CAGR) of 5.96% from 2025 to 2035. The focus on early intervention may also lead to improved patient outcomes and reduced healthcare costs.

Advancements in Treatment Options

Innovations in treatment modalities for Myasthenia Gravis are significantly influencing the Global Myasthenia Gravis Disease Market Industry. The development of monoclonal antibodies and immunotherapies has transformed patient management, offering more effective and targeted approaches. For instance, therapies such as eculizumab have shown promising results in clinical trials, leading to improved patient outcomes. As these advanced treatments gain regulatory approval and enter the market, they are expected to contribute to the market's growth trajectory, potentially reaching a value of 3.8 USD Billion by 2035. The ongoing research and development efforts indicate a robust pipeline of therapies that may enhance patient quality of life.

Emerging Markets and Global Expansion

The Global Myasthenia Gravis Disease Market Industry is experiencing growth in emerging markets, where increased healthcare investments and rising awareness are driving demand for treatment options. Countries in Asia-Pacific and Latin America are witnessing a surge in healthcare infrastructure development, which is likely to enhance access to Myasthenia Gravis therapies. This expansion into new markets presents significant opportunities for pharmaceutical companies. As these regions develop, the market is projected to grow, potentially reaching 3.8 USD Billion by 2035. The increasing focus on healthcare access in these areas may lead to improved patient outcomes and a broader market reach.

Increasing Prevalence of Myasthenia Gravis

The Global Myasthenia Gravis Disease Market Industry is witnessing a notable rise in prevalence rates, which is likely to drive market growth. Current estimates suggest that the incidence of Myasthenia Gravis is approximately 20 per 100,000 individuals globally. This increasing prevalence necessitates enhanced healthcare resources and treatment options, thereby expanding the market. As awareness of the disease grows, more patients are diagnosed, contributing to the projected market value of 2.01 USD Billion in 2024. The rising number of patients emphasizes the need for innovative therapies and management strategies, which could further stimulate market dynamics.

Market Segment Insights

Myasthenia Gravis Disease Market Treatment Type Insights

The Myasthenia Gravis Disease Market segmentation around Treatment Type reflected a robust landscape with diverse therapeutic options, contributing significantly to the overall market dynamics.In 2024, the market showcased substantial valuations, with Immunosuppressants leading the charge at 0.7 USD Billion, underscoring their critical role in managing the autoimmune aspects of Myasthenia Gravis. This treatment category not only represented a majority holding within the market but also emphasized the ongoing need for effective immunosuppressive therapies in patient care.

Following closely, Monoclonal Antibodies were valued at 0.5 USD Billion, harnessing targeted approaches to modulation of the immune response, thus reinforcing their significance in therapeutic regimens for Myasthenia Gravis. Cholinesterase Inhibitors, valued at 0.45 USD Billion, remained pivotal in enhancing neuromuscular transmission, providing essential symptomatic relief. The Plasmapheresis approach, valued at 0.25 USD Billion, gained traction for its efficiency in rapidly reducing circulating antibodies, indicating a growing awareness among practitioners about its immediate benefits during exacerbations.

Meanwhile, Intravenous Immunoglobulin, with a valuation of 0.11 USD Billion, signified a more niche yet critical treatment modality, reflecting its use in acute management scenarios that warrant high-dose immunomodulation.As the Myasthenia Gravis Disease Market continued to evolve, trends such as personalized medicine and advancements in biotechnology are expected to drive innovation across these therapeutic avenues, enhancing treatment efficacy and patient outcomes while simultaneously addressing challenges related to accessibility and affordability within the global healthcare framework.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Myasthenia Gravis Disease Market Diagnosis Method Insights

The Myasthenia Gravis Disease Market, within the Diagnosis Method segment, is crucial for identifying and understanding this chronic autoimmune disorder. Among various techniques, Electromyography plays a pivotal role in detecting nerve-to-muscle transmission problems, while Blood Tests, particularly for antibodies, provide essential insights for clinicians.

CT Scans and MRIs offer advanced imaging capabilities, enabling detailed visualization of the thymus gland, which is often involved in Myasthenia Gravis. The Edrophonium Test, being a rapid assessment method, aids in diagnosing the condition effectively, showcasing its relevance.

The increasing prevalence of Myasthenia Gravis, combined with a rise in healthcare expenditure, acts as a key growth driver for the Myasthenia Gravis Disease Market revenue. Additionally, the market is influenced by a trend towards more precise and non-invasive diagnostic methods, aligning with patient preferences and enhancing clinical outcomes.

However, challenges such as the need for skilled professionals to administer tests could impact access to diagnosis. Overall, advancements in technology and a growing focus on early detection signify promising opportunities within the Myasthenia Gravis Disease Market segmentation.

Myasthenia Gravis Disease Market Patient Demographics Insights

The Myasthenia Gravis Disease Market focuses significantly on Patient Demographics as a key component of its segmentation. Patient Demographics divide into categories such as Adults, Children, and the Elderly, each with unique needs.Adults represent a significant portion of the cases, as they typically exhibit a higher prevalence of the disease due to age-related factors and increased exposure to environmental triggers.

The Elderly segment also holds considerable importance, as age can exacerbate symptoms and lead to complications, necessitating specialized care.Meanwhile, Children, although representing a smaller demographic within the market, require specific interventions and therapies designed for their growing bodies, making targeted medical approaches crucial.

The growth drivers for this market include an increasing awareness of myasthenia gravis, improved diagnostic methods, and advancements in treatment. However, challenges such as limited clinical data and varying disease presentation across demographics can affect market growth.Overall, understanding the demographics is vital for targeted strategies in the Myasthenia Gravis Disease Market, as it shapes treatment protocols and enhances patient outcomes.

Myasthenia Gravis Disease Market Distribution Channel Insights

The Myasthenia Gravis Disease Market has shown noteworthy growth, particularly within its Distribution Channel segment. The distribution landscape encompasses various channels, including Hospitals, Pharmacies, and Online Stores, each playing a crucial role in ensuring patient access to medications.Hospitals are vital as they provide specialized care and treatment, often being the first point of contact for patients. Pharmacies hold a significant share, serving as convenient access points for patients requiring ongoing medication and consultations.

Meanwhile, Online Stores are becoming increasingly popular due to their convenience and broader reach, especially post-pandemic, facilitating easier access to medications for patients in remote areas. The Myasthenia Gravis Disease Market revenue is expected to thrive due to a combination of factors, including advancements in treatment options and increased public awareness.

Market growth is also driven by technological innovations, although it faces challenges such as regulatory hurdles and supply chain disruptions. The potential for collaboration across these channels presents ample opportunities for strengthening distribution strategies and enhancing patient outcomes in the Myasthenia Gravis Disease Market.

Get more detailed insights about Myasthenia Gravis Disease Market Research Report - Forecast to 2035

Regional Insights

The Myasthenia Gravis Disease Market was significantly influenced by its regional segmentation, which reveals varying market dynamics across different geographical areas.In 2024, North America held a valuation of 0.85 USD Billion, making it a key player in the market, with a projected increase to 1.55 USD Billion by 2035. This dominance was attributed to advanced healthcare infrastructure and prevalence of the disease.

Europe followed, valued at 0.55 USD Billion in 2024, and expected to reach 1.05 USD Billion by 2035, indicating significant research and development initiatives in the region. The Asia Pacific segment was valued at 0.3 USD Billion in 2024, growing to 0.6 USD Billion by 2035, reflecting increasing awareness and healthcare advancements.

South America and the Middle East and Africa segments were valued at 0.15 USD Billion and 0.16 USD Billion respectively in 2024, with both projected to double by 2035. While underrepresented, these regions experienced growth due to increasing healthcare investments and improved access to treatments.Overall, the market dynamics across these regions showcased diverse growth drivers and varying levels of healthcare readiness, which were pivotal for the Myasthenia Gravis Disease Market statistics and trends.

Myasthenia Gravis Disease Market Regional Insights

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The Myasthenia Gravis Disease Market is characterized by a competitive landscape that is rapidly evolving as new therapies and innovations emerge. This market is driven by increased awareness, advancements in treatment options, and a growing patient population diagnosed with this neuromuscular disorder.

The competitive insights reflect not only the presence of established pharmaceutical companies but also highlight the strategies adopted by these players to enhance their market positioning.The market is influenced by ongoing research and development, regulatory approvals, and collaborations that shape the future of therapies available for myasthenia gravis, showcasing a dynamic interplay between innovation and market demand.

Pfizer stands as a significant player in the Myasthenia Gravis Disease Market due to its robust portfolio and commitment to addressing rare diseases. The company's presence in this market is strengthened by its extensive research capabilities and experience in developing neuromuscular disorder treatments.Pfizer's strengths lie in its established brand reputation, extensive distribution networks, and resources dedicated to clinical trials that aim to refine treatment methodologies for myasthenia gravis. The company focuses on delivering effective therapies while maintaining compliance with global health standards.

Through innovation and the utilization of cutting-edge research, Pfizer aims to enhance the lives of patients afflicted with this condition, playing a pivotal role in shaping the future market landscape.Mallinckrodt Pharmaceuticals contributes uniquely to the Myasthenia Gravis Disease Market by offering specialized therapies that target the nuances of this condition. The company is known for its commitment to developing and marketing innovative treatments that help manage myasthenia gravis effectively.

With a strong focus on the global region, Mallinckrodt Pharmaceuticals has established a solid presence through its key products which include therapies designed specifically for the management of autoimmune indications.The company's strengths are underscored by its dedication to quality, significant investments in research and development, and strategic collaborations that bolster its market position.

Mallinckrodt has also pursued mergers and acquisitions to diversify its offerings and enhance its capabilities in addressing the needs of patients suffering from myasthenia gravis. This strategic approach fosters a competitive edge in an increasingly crowded market, positioning Mallinckrodt as a reliable partner in the treatment landscape for this neurological disease.

Key Companies in the Myasthenia Gravis Disease Market market include

Industry Developments

The FDA approved Johnson & Johnson's FcRn-blocking monoclonal antibody, Imaavy (nipocalimab), on April 30, 2025, making it the first to be approved in the United States for the treatment of generalized myasthenia gravis (gMG) in patients 12 years of age and older. This establishes the medication as a crucial therapeutic choice that targets IgG-mediated illness processes.

The FDA authorized Argenx's Vyvgart Hytrulo prefilled syringe on April 10, 2025, allowing adult gMG and CIDP patients to self-administer their efgartigimod/hyaluronidase combo at home. This step is anticipated to increase patient convenience and accessibility.Positive Phase 3 findings from the MINT study, which showed that Uplizna (inebilizumab) significantly improved daily living activities in AChR+ gMG patients during a 52-week period, were announced by Amgen on March 14, 2025.

The FDA authorized the first pediatric treatment for gMG on March 12, 2025, when it extended the use of Soliris (eculizumab) to kids patients six years of age and up. UCB received FDA clearance in October 2023 for Zilbrysq (zilucoplan), a subcutaneous complement C5 inhibitor for adult AChR+ gMG patients.In June 2023, the company introduced Rystiggo (rozanolixizumab), an FcRn modulator for adult gMG that is licensed in the US and the EU. The gMG environment has a strong diversity of treatment approaches, as seen by these recent regulatory accomplishments.

Future Outlook

Myasthenia Gravis Disease Market Future Outlook

The Global Myasthenia Gravis Disease Market is projected to grow at a 5.96% CAGR from 2025 to 2035, driven by advancements in therapies, increasing awareness, and enhanced diagnostic tools.

New opportunities lie in:

Develop novel biologics targeting specific autoimmune pathways in Myasthenia Gravis. Invest in telemedicine solutions for remote patient monitoring and management. Create educational programs to raise awareness and improve early diagnosis rates.

By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased patient engagement.

Market Segmentation

Myasthenia Gravis Disease Market Treatment Type Outlook

Immunosuppressants
Cholinesterase Inhibitors
Monoclonal Antibodies
Plasmapheresis
Intravenous Immunoglobulin

Myasthenia Gravis Disease Market Diagnosis Method Outlook

Electromyography
Blood Tests
CT Scan
MRI
Edrophonium Test

Myasthenia Gravis Disease Market Distribution Channel Outlook

Hospitals
Pharmacies
Online Stores

Myasthenia Gravis Disease Market Patient Demographics Outlook

Adults
Children
Elderly

Report Scope

Report Attribute/Metric	Details
Market Size 2024	2.01(USD Billion)
Market Size 2035	3.07 (USD Billion)
Compound Annual Growth Rate (CAGR)	7.92% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Pfizer, Mallinckrodt Pharmaceuticals, BristolMyers Squibb, Amgen, UCB, Horizon Therapeutics, Sanofi, Exelixis, Johnson & Johnson, Roche, AstraZeneca, Eli Lilly, Teva Pharmaceutical Industries, Novartis, Grifols
Segments Covered	Treatment Type, Diagnosis Method, Patient Demographics, Distribution Channel, Regional
Key Market Opportunities	Novel therapies and treatments, Increased diagnostic advancements, Growing patient awareness programs, Expanding clinical trial pipeline, Telehealth services for management
Key Market Dynamics	Rising prevalence of autoimmune diseases, Increasing R&D investments, Growing awareness and diagnosis, Advancements in treatment options, High unmet medical needs
Countries Covered	North America, Europe, APAC, South America, MEA
Market Size 2025	1.43 (USD Billion)